Pear Therapeutics already has three FDA-approved prescription digital therapeutics (DTx) on the market – but it seems that isn’t enough to ensure a stable financial positi
An app to treat insomnia has become the first digital therapeutics (DTx) to be approved for marketing by the Ministry of Food and Drug Safety (MFDS) in South Korea.
Newly diagnosed cancer patients across the UK will get free access to digital mental health therapies, thanks to a new partnership between Macmillan Cancer Support and Big Health.<
After a non-committal appraisal of Big Health's Sleepio app for insomnia last November in draft guidance from NICE, the cost-effectiveness agency has come out in favour of the digital thera
A digital therapeutic (DTx) developed to help people suffering from insomnia has been shown to improve sleep and mental health in people recovering from a stroke in a clinical trial.
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio